Publication: 3314

Publication: 3314

Survival, Pathologic Response, and Genomics in CALGB 40601 (Alliance), a Neoadjuvant Phase III Trial of Paclitaxel-Trastuzumab With or Without Lapatinib in HER2-Positive Breast Cancer

PubMed

PMC

QxMD

DOI

Google Scholar

Citation:: J Clin Oncol vol 38 (35) 4184-4193

Year:: 2020
Type:: Manuscript
Funding:: NCTN
Endpoint:: Secondary
Analysis:: Primary
Data Sharing:: No-Data-Sharing
Status:: Presented/Published
Citation Status:: pmc-release

Note:

Methodological:: No
Biospecimen:: Yes
SDC:: No
Book Volume:: 10

Parents:: 2540 2758 2759 3072 3126
Children:: None

Program:: OGC
Primary Committee:: Breast
Sec. Committees:

Pharmas:: GlaxoSmithKline
Grants:: U10CA180821, U10CA180882, U24CA196171, R01CA229409, UG1CA233160, UG1CA233180, UG1CA233290, UG1CA233329, UG1CA233333, UG1CA233373, P50-CA58223, U10CA180888, UG1CA233160 (SWOG)

Corr. Author:
Authors:: Aranzazu Fernandez-Martinez Ian E. Krop David W. Hillman Mei-Yin Polley Joel S. Parker Lucas Huebner Katherine A. Hoadley Jonathan Shepherd Sara Tolaney N. Lynn Henry Chau Dang Lyndsay Harris Donald Berry Olwen Hahn Clifford Hudis Eric Winer Ann Partridge Charles M. Perou Lisa A. Carey

Networks:: LAPS-CT018, LAPS-IL057, LAPS-MA036, LAPS-NC007, LAPS-NY016, LAPS-UT003

Study: CALGB-40601
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:: 3

Keywords:: ORIGINAL REPORTS, Breast Cancer